



Feng Tian, Ph.D.

*Chairman, Chief Executive Officer and
President*

Feng Tian, Ph.D., has served as our director, Chief Executive Officer and President since July 2018, including as Chairman of the board of directors since November 2020. He has held positions of increasing responsibility since joining in 2004. Previously, as Chief Scientific Officer from 2015 to 2018, Dr. Tian oversaw our research and development. Prior to joining Ambrx, Dr. Tian conducted his post doctoral studies at The Scripps Research Institute in Professor Peter G. Schultz's group, where his work involved catalytic antibodies, non-natural amino acid incorporation, and biosensors. Dr. Tian received his Ph.D. in Chemistry from the University of Florida, with a dissertation in the field of Physical Organic Chemistry, under the supervision of Professor William R. Dolbier, Jr. He received his B.S. in Chemistry from Peking University. Dr. Tian is a co-founder of LuxVitae Therapeutics Inc.